Viridian Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 20, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	2,223	1,467	1,036	1,100	378	53
Market Cap Growth	51.95%	41.55%	-5.81%	191.32%	618.50%	286.62%
Enterprise Value	1,987	944	895	835	333	36
Last Close Price	23.59	18.20	19.90	26.60	17.30	13.06
PS Ratio	36.84	5028.17	3647.53	663.46	144.94	61.23
PB Ratio	5.19	2.26	2.59	2.98	2.29	0.54
P/TBV Ratio	8.30	3.15	4.86	4.65	7.97	-
EV/Sales Ratio	33.07	3236.51	3150.76	503.65	127.79	41.48
Debt / Equity Ratio	0.05	0.03	0.05	0.01	0.00	0.00
Net Debt / Equity Ratio	-0.93	-1.03	-1.03	-1.06	-1.05	-1.06
Net Debt / EBITDA Ratio	1.44	2.33	1.79	3.13	2.47	3.16
Net Debt / FCF Ratio	1.43	2.98	2.46	4.43	3.58	4.26
Asset Turnover	0.11	0	0.00	0.01	0.02	0.01
Quick Ratio	11.06	14.99	17.93	12.73	14.48	11.96
Current Ratio	11.28	15.43	18.27	12.93	14.68	12.14
Return on Equity (ROE)	-49.89%	-48.48%	-56.80%	-44.57%	-51.61%	-163.07%
Return on Assets (ROA)	-30.08%	-30.32%	-34.37%	-26.28%	-29.75%	-31.36%
Return on Capital Employed (ROCE)	-61.70%	-43.10%	-54.90%	-33.40%	-41.90%	-33.60%
Earnings Yield	-9.41%	-17.78%	-20.76%	-11.05%	-18.49%	-172.21%
FCF Yield	-12.51%	-15.33%	-16.16%	-8.05%	-12.79%	-46.39%
Buyback Yield / Dilution	-34.66%	-51.68%	-39.48%	-169.22%	-235.07%	-70.27%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.